Pilot randomized, controlled trial of pramipexole to augment antipsychotic treatment

Eur Neuropsychopharmacol. 2012 Jun;22(6):415-8. doi: 10.1016/j.euroneuro.2011.10.002. Epub 2011 Dec 7.


The preferential dopamine D(3)-agonist pramipexole (4.25±0.38 mg/day) or placebo were added for up to 12 weeks to ongoing antipsychotic treatment for 24 adult patients with DSM-IV schizophrenia or schizoaffective disorder. Pramipexole was generally well-tolerated (82% trial-completion), and yielded greater decreases in PANSS-total scores (drug/placebo=2.1; p=0.04), with similar decreases in PANSS positive and negative scores and 6.7-fold greater reduction of serum prolactin concentrations compared to placebo. There were no differences in ratings of mood, cognition or extrapyramidal symptoms, all of which were low at intake.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antioxidants / therapeutic use*
  • Antipsychotic Agents / therapeutic use*
  • Benzothiazoles / therapeutic use*
  • Cross-Sectional Studies
  • Double-Blind Method
  • Drug Synergism
  • Female
  • Humans
  • Male
  • Middle Aged
  • Outpatients
  • Pilot Projects
  • Pramipexole
  • Prolactin / blood
  • Psychotic Disorders / drug therapy*
  • Schizophrenia / drug therapy*
  • Young Adult


  • Antioxidants
  • Antipsychotic Agents
  • Benzothiazoles
  • Pramipexole
  • Prolactin